Company Description
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases.
The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system.
The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.
Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 174 |
| CEO | Cameron McDonough |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 655 7500 |
| Website | generationbio.com |
Stock Details
| Ticker Symbol | GBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001733294 |
| CUSIP Number | 37148K100 |
| ISIN Number | US37148K1007 |
| Employer ID | 81-4301281 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Geoffrey McDonough M.D. | President, Chief Executive Officer and Director |
| Dr. Matthew Norkunas M.B.A., M.D. | Chief Financial Officer |
| Dr. Matthew Stanton Ph.D. | Chief Scientific Officer |
| Yalonda Howze J.D. | Chief Legal Officer and Secretary |
| Dr. Mark D. Angelino Ph.D. | Co-Founder |
| Dr. Robert Kotin Ph.D. | Co-Founder |
| Antoinette Paone M.B.A., M.S. | Chief Operating Officer |
| Jasmin Tower | Chief Human Resources Officer |
| Dr. Phillip Samayoa Ph.D. | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 15, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | UPLOAD | Filing |
| Aug 7, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |